Publication The EU HTA process should be considered a learning system Interview in Market Access & Health Policy 01/2024 more
Publication How fast will the EU HTA child grow? Estimation of the number of procedures of the first years of implementation more
Publication Orphan vs. Non-Orphan Drugs in Germany Is there really a need for adjustment in the benefit assessment? more
Blog Combination discount - a bureaucratic monster Implementation regulation of the combination discount according to section 130e SGB V named by the BMG more
Blog Few therapies, a lot of research Therapy options for paediatric dementia (neuronal ceroid lipofuscinosis) more
Event Market access of repurposed drugs 13th of Dec 2024 Steven Krüger Training on AMNOG and non-AMNOG medicinal products Register here. more
Event Ask the experts III 10th of Dec 2024 Dr. rer. nat. Ingo Hantke EU HTA market access strategy panel Register here. more
Event ISPOR Europe 17th to 20th of Nov 2024 Dr. rer. nat. Lydia Frick Meet our experts at our booth 827. more
Event World Orphan Drug Congress 2024 22nd to 25th of Oct 2024 Fenja Lang Meet SKC at booth 109! more
